187 related articles for article (PubMed ID: 18929733)
1. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians.
Paschall S; Kaunitz AM
Contraception; 2008 Nov; 78(5):370-6. PubMed ID: 18929733
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density testing, and bisphosphonate and oestrogen prescribing associated with depot medroxyprogesterone acetate utilization-The impact of the boxed warning.
Eworuke E; Popat V; Moeny DG
J Clin Pharm Ther; 2017 Aug; 42(4):483-494. PubMed ID: 28543135
[TBL] [Abstract][Full Text] [Related]
3. Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
Cromer BA; Scholes D; Berenson A; Cundy T; Clark MK; Kaunitz AM;
J Adolesc Health; 2006 Aug; 39(2):296-301. PubMed ID: 16857545
[TBL] [Abstract][Full Text] [Related]
4. The contraceptive use of Depo-Provera in U.S. adolescents.
Pinkston Koenigs LM; Miller NH
J Adolesc Health; 1995 May; 16(5):347-9. PubMed ID: 7662682
[TBL] [Abstract][Full Text] [Related]
5. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health.
Guilbert ER; Brown JP; Kaunitz AM; Wagner MS; Bérubé J; Charbonneau L; Francoeur D; Gilbert A; Gilbert F; Roy G; Senikas V; Jacob R; Morin R
Contraception; 2009 Mar; 79(3):167-77. PubMed ID: 19185668
[TBL] [Abstract][Full Text] [Related]
6. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
7. Depot medroxyprogesterone acetate (DMPA, Depo-Provera) in adolescents: what is next after the FDA black box warning.
Omar H; Kives S
J Pediatr Adolesc Gynecol; 2005 Jun; 18(3):183. PubMed ID: 15970252
[No Abstract] [Full Text] [Related]
8. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
[TBL] [Abstract][Full Text] [Related]
9. Removing the black box warning for depot medroxyprogesterone acetate.
Kaunitz AM; Grimes DA
Contraception; 2011 Sep; 84(3):212-3. PubMed ID: 21843682
[No Abstract] [Full Text] [Related]
10. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate.
Clark MK; Sowers MR; Nichols S; Levy B
Fertil Steril; 2004 Dec; 82(6):1580-6. PubMed ID: 15589863
[TBL] [Abstract][Full Text] [Related]
11. Effects of Food and Drug Administration warnings on antidepressant use in a national sample.
Olfson M; Marcus SC; Druss BG
Arch Gen Psychiatry; 2008 Jan; 65(1):94-101. PubMed ID: 18180433
[TBL] [Abstract][Full Text] [Related]
12. Depot-medroxyprogesterone acetate: an update.
Bakry S; Merhi ZO; Scalise TJ; Mahmoud MS; Fadiel A; Naftolin F
Arch Gynecol Obstet; 2008 Jul; 278(1):1-12. PubMed ID: 18470526
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density.
Johnson CC; Burkman RT; Gold MA; Brown RT; Harel Z; Bruner A; Stager M; Bachrach LK; Hertweck SP; Nelson AL; Nelson DA; Coupey SM; McLeod A; Bone HG
Contraception; 2008 Apr; 77(4):239-48. PubMed ID: 18342646
[TBL] [Abstract][Full Text] [Related]
14. FDA board investigates Depo-Provera safety.
Contracept Technol Update; 1983 Mar; 4(3):25-7. PubMed ID: 12266161
[TBL] [Abstract][Full Text] [Related]
15. 'Black box' warning added to contraceptive injection.
FDA Consum; 2005; 39(2):3. PubMed ID: 16124078
[No Abstract] [Full Text] [Related]
16. Depo-Provera use in an Australian metropolitan practice.
Fraser IS; Dennerstein GJ
Med J Aust; 1994 May; 160(9):553-6. PubMed ID: 8164553
[TBL] [Abstract][Full Text] [Related]
17. [Status of bone mineral density after the long-standing application of contraception Depo-Provera].
Zeman S; Havlík P; Zemanová J; Němec D
Ceska Gynekol; 2013 Jan; 78(1):116-24. PubMed ID: 23607391
[TBL] [Abstract][Full Text] [Related]
18. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling.
Shaarawy M; El-Mallah SY; Seoudi S; Hassan M; Mohsen IA
Contraception; 2006 Oct; 74(4):297-302. PubMed ID: 16982229
[TBL] [Abstract][Full Text] [Related]
19. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
Contraception; 2004 Feb; 69(2):99-104. PubMed ID: 14759613
[TBL] [Abstract][Full Text] [Related]
20. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
Kaunitz AM
Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
